CTLA4 and melanoma: In the recent phase III trials testing the adjuvant anti-PD-1 in resected stage III melanoma, the first-line anti-PD-1 antibody in combination with chemotherapy in metastatic NSCLC, and the combination of anti-PD-1 and anti-CTLA4 antibodies in NSCLC with a high mutational burden, the benefit of immunotherapy did not correlate with the PD-L1 expression level [79,80,81].